Expert outlines advantages of batteryless sacral neuromodulation device

Six-month data evaluating a battery-free percutaneous sacral neuromodulation (pSNM) device indicated that 84.2% of patients implanted achieved a 50% or greater reduction in urgent leaks.

The data on Neuspera’s pSNM device were presented at the 2025 Winter Meeting of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) in Rancho Mirage, California, and were shared in a news release from Neuspera Medical.¹

In a recent video interview with Urology Times®, study investigator Colin Goudelocke, MD, was asked how he envisioned the integration of Neurspera's pSNM into the current treatment paradigm for urge urinary incontinence, and what he saw as key factors that might influence its adoption among urologists and patients. He commented that in contrast to previous years, when there was dearth of treatments for overactive bladder, today, “It's almost an embarrassment of riches.”

“I'd always rather have too many choices, too many tools in the toolbox, rather than too few,” Goudelocke added.

However, having so many options raises the question of which treatment is appropriate for which patient, he said. For a device such as Neuspera’s pSNM, which is much smaller due to its lack of a battery, patients who might particularly benefit include those with lower body mass index and who are more active, Goudelocke noted.

“I sometimes have patients who are really, really active, and they'll get hit by something or struck by something at the site of their generator, and that can cause some discomfort or pain,” he said.

Goudelocke also commented that Neuspera’s system might be appealing to patients who want to take an active role in their treatment. In contrast, “There probably are patients that do want just a “set it and forget it” neuromodulator, and this is not going to be the right thing for them,” he said.

Another consideration is cosmesis. “There are patients who want to know, ‘am I going to see it when I’m in a changing room or changing clothes? Is it going to show through a bathing suit’”? Goudelocke said.

On the clinician side, Goudelocke highlighted the benefit of not having to put a generator in when implanting the device.

“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat…and I think that might be attractive to some people,” Goudelocke said.

REFERENCE

1. Neuspera Medical announces landmark six-month clinical trial results for the first battery-free percutaneous sacral neuromodulation (pSNM) system for urgency urinary incontinence management. News release. Neuspera Medical Inc. February 26, 2025. Accessed February 28, 2025. https://www.prnewswire.com/news-releases/neuspera-medical-announces-landmark-six-month-clinical-trial-results-for-the-first-battery-free-percutaneous-sacral-neuromodulation-psnm-system-for-urgency-urinary-incontinence-management-302385607.html